LANGUAGE
KOREAN
ENGLISH
LOCATION
COMPANY
R&D
R&D Institute
GMP Center
Clinical Development Status
Publications
PRODUCTS
1st Generation
Overview
CARTISTEM
®
PNEUMOSTEM
®
2nd Generation
Overview
SMUP-IA-01
SMUP-IV-01
R&D Inquiries
BUSINESS
CDMO
Quality System
CDMO Service
Quality Control
Global CDMO
CDMO Inquiries
CELLTREE Cord Blood Bank
MOVITA Nutritional Supplements
IR
Stock Information
Disclosure
Financial Information
IR Inquiries
PR
MEDIPOST on Media
Corporate Brochure
CONTACT US
Customer Center
R&D Inquiries
CDMO Inquiries
IR Inquiries
Search Results
Inquiries on CDMO Service
2024/01/08
MEDIPOST Submits Application for Product Authorization Amendment to Add Ankle In…
2023/12/27
MEDIPOST Selected for a Government-Supported R&D Project Worth KRW 13 billi…
2023/10/04
MEDIPOST’s CARTISEM®, Umbilical Cord Blood-derived Stem Cell Transplant Surgery…
2023/05/02
Global CDMO
2023/02/08
Biologics Quality Control Service
2023/02/08
CDMO Service
2023/02/08
Quality System
2023/02/08
MEDIPOST Treats First Subject with CARTISTEM® in Japan Phase 3 Clinical Trial, A…
2023/01/16
MEDIPOST Enhances its Partnership with Canada’s OmniaBio in Collaboration…
2022/12/01
Disclosure
2022/10/26
Medipost to launch a CDMO business for cell and gene therapy products in Korea b…
2022/10/17
1
2
3
4
…
14
Next
Menu